Potassium2026-07

BRCA2-deficient endothelium: a hidden catalyst in angiotensin II-induced vascular injury.

Singh Aman, Bu Shuhan, Perron Alexander V, Bhatt Kriti S et al. — Journal of hypertension

Summary

This study explores how a genetic change in the BRCA2 gene, known for cancer risk, might also affect blood vessel health. Researchers found that cells lacking BRCA2 become more vulnerable to damage from a hormone called angiotensin II, which plays a key role in blood pressure regulation. This suggests that individuals with BRCA2 mutations might face a higher risk of developing high blood pressure and related heart problems.

AI-generated summary — read the original

Key points

Mutations in the BRCA2 gene, linked to cancer, may also increase the risk of vascular problems.
Cells lacking BRCA2 become more susceptible to damage from angiotensin II, a hormone that raises blood pressure.
This increased vulnerability could contribute to a higher risk of high blood pressure and heart complications in BRCA2 mutation carriers.
The study identifies a new genetic pathway potentially involved in cardiovascular disease risk.

What the study looked at

What question the study asked: This research investigated whether a deficiency in the BRCA2 gene, commonly associated with increased cancer risk, also plays a role in how blood vessels respond to angiotensin II, a hormone crucial for blood pressure regulation and a major factor in hypertension. How it was studied: Researchers conducted experiments on cultured endothelial cells, which line blood vessels. They specifically silenced the BRCA2 gene in these cells to mimic a deficiency and then treated them with angiotensin II. They observed various markers of cell damage, inflammation, and function, as well as the activity of related signaling pathways. What it found: The study found that when BRCA2 was deficient, endothelial cells experienced significantly more damage, oxidative stress, and inflammation when exposed to angiotensin II. Their ability to migrate and form new blood vessels was also impaired. These findings suggest that a lack of functional BRCA2 makes blood vessel cells more vulnerable to the harmful effects of angiotensin II, potentially increasing the risk of high blood pressure and related cardiovascular issues in individuals with BRCA2 mutations.

Dietary takeaway

This study suggests a genetic link to vascular vulnerability, highlighting how BRCA2 mutations might increase the risk of hypertension-related complications. While this research didn't specifically examine nutrition, maintaining a balanced diet rich in potassium — found abundantly in fruits, vegetables, and legumes — is generally recommended to help manage blood pressure and support overall heart health. However, it's crucial to remember that this single study alone doesn't provide specific dietary recommendations, and more comprehensive research is needed to understand the full interplay between genetics, diet, and cardiovascular health.

Abstract

BACKGROUND: Mutations in the breast cancer susceptibility gene 2 (BRCA2) are well known to increase the risk of breast and ovarian cancers. Emerging evidence indicates that BRCA2 mutation carriers exhibit increased vascular disorder and may develop endothelial dysfunction, a key mechanism underlying hypertension. Angiotensin II (Ang II), a central effector of the renin-angiotensin system, is a key regulator of blood pressure and a major driver of hypertension, promoting endothelial injury through oxidative stress, inflammation, and impaired nitric oxide (NO) bioavailability. However, the role of endothelial BRCA2 in Ang II-induced endothelial dysfunction remains unknown. METHODS: BRCA2 was silenced in cultured endothelial cells and following Ang II treatment, ROS generation, DNA damage, apoptosis, inflammation, NO production, migration, angiogenic capacity, Ang II receptors and related signaling pathways were assessed. RESULTS: BRCA2 deficiency exacerbated Ang II-induced increases in ROS, DNA damage, and apoptosis, along with impaired functional capacity, including reduced migration and angiogenesis. NO production was suppressed, accompanied by increased micronuclei formation and enhanced c-Jun N-terminal kinase (JNK) activation. In addition, both BRCA2 loss and Ang II treatment upregulated the Ang II receptor AT1R. Pharmacological inhibition of AT1R attenuated Ang II-induced increases in DNA damage and apoptosis in BRCA2-deficient endothelial cells. CONCLUSION: These findings provide the first pharmacogenomic evidence that BRCA2 deficiency sensitizes endothelial cells to Ang II-induced dysfunction, suggesting that BRCA2 mutation carriers may be at increased risk for hypertension-associated cardiovascular complications.

View on PubMed →DOI: 10.1097/HJH.0000000000004407